

# **GTSAB REPORT**

## **Recombinant DNA Advisory Committee**

**December 4, 2012**



# Protocols Submitted for 4th Quarter 2012

▶ **15 Total submissions**

**Disease indications for the protocols not selected:**

- **7 Cancer**
- **1 Sickle-cell disease**
- **1 HIV vaccine**


- **Vectors:**

- **1 Adenovirus**
- **2 Plasmid**
- **2 Retrovirus**
- **2 Lentivirus**
- **1 HSV**
- **1 RNA transfer**


# Summary of Annual Submissions

- ▶ A total of 59 protocols were submitted for review at the 2012 RAC meetings

## 2012 Gene Transfer Trials By Clinical Indication



# 2012 Gene Transfer Trials By Delivery System



\*e.g. modified bacteria, transposon

# **Serious Adverse Events**

**10 serious adverse events were reviewed by the GTSAB from 9 protocols, including initial and follow-up reports. No events will be discussed today.**



# **Opening of New Protocols 4th Quarter 2012**

- ▶ **12 Protocols notified OBA of enrollment (MIC1 submission).**
  - ▶ **Two of the 12 were reviewed at a public meeting.**
  - ▶ **Information on trials not selected will be available with these slides on OBA's Website after the meeting.**
- 

# **A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients with Stable Ischemic Stroke** (OBA Protocol #880 Reviewed December 2007)

- ▶ **SB623 cells are adult bone-marrow-derived cells that have been transiently transfected with a plasmid construct encoding the intracellular domain of human Notch-1**
- ▶ **A one year study was performed in immune-compromised rats to examine the tumorigenicity of the notch-1 intracellular domain. Neither tumor formation nor cell proliferation were observed.**
- ▶ **The revised clinical study no longer employs cyclosporine A or any other form of immunosuppression.**


# **A Randomized Phase I/II Trial Using a GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) Vaccine in Combination with CCL21 for Patients with Stage IV Adenocarcinoma of the Lung**

(OBA Protocol #1087 Reviewed March 2011)

- ▶ **Based on data from a previous trial using the GM-CSF and CD40L-expressing bystander cell line, it is expected that there will be a time interval between dosing and development of an anti-tumor immune response. The inclusion and exclusion criteria have been updated to define more precisely patients whose disease is not likely to progress significantly during the course of the trial.**
- ▶ **Subjects have been provided a study card containing summary information regarding the trial and the investigator's contact information so that if the subject seeks emergency treatment at an unaffiliated hospital that information will be available to the treatment team.**

**UPDATE: Protocol #0604-776: A Phase I  
Study of CD19 Chimeric Receptor expressing  
T Lymphocytes in B-Cell Non-Hodgkins  
Lymphoma and Chronic Lymphocytic  
Leukemia**

**Carlos Ramos, M.D.  
Assistant Professor  
Department of Medicine  
Section of Hematology-Oncology  
Baylor College of Medicine**





## **▶ PROTOCOLS INITIATED BUT NOT REVIEWED AT A PUBLIC MEETING.**

- A Phase I Trial for the Treatment of Purine Analog-Refractory Chronic Lymphocytic Leukemia Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (OBA Protocol #721)**
- A Randomized Phase II Trial Using Dendritic Cells Transduced with an Adenoviral Vector Containing the p53 Gene to Immunize Patients with Extensive Stage Small Cell Lung Cancer in Combination with Chemotherapy With or Without All Trans Retinoic Acid (OBA Protocol #857)**
- Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase I Dose Escalation Study (OBA Protocol #1086)**
- Phase I Study to Evaluate the Antitumor Activity and Safety of Duke-002-vrp (huher2-ecd+tm) (avx901), an Alphaviral Vector Encoding the Her2 Extracellular Domain and Transmembrane Region, in Patients with Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (Her2+) Cancers Including Breast Cancer(OBA Protocol #1126)**

▶ **PROTOCOLS INITIATED BUT NOT REVIEWED AT A PUBLIC MEETING.**

- **A Phase I/II Randomized, Double-Blind, Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Needle-free Dermal Injection to Cohorts of Adults Receiving Surgical Incisions (OBA Protocol #1131)**
- **A Phase I/II Study of Cellular Immunotherapy with Donor Central Memory - Derived Virus-Specific CD8+ T-Cells Engineered to Target CD19 for CD19+ Malignancies after Allogeneic Hematopoietic Stem Cell Transplant (OBA Protocol #1150)**
- **A Single-Arm, Open-Label, Phase 2 Study of JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-Naïve Patients with Advanced Hepatocellular Carcinoma (HCC) (OBA Protocol #1154)**
- **A Phase IB Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination with Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma(OBA Protocol #1160)**

▶ **PROTOCOLS INITIATED BUT NOT REVIEWED AT A PUBLIC MEETING.**

- **A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure (OBA Protocol #1167)**